Parameter
| Biomarker | Fusobacterium nucleatum | Full name | Fusobacterium nucleatum | Molecular Type | Pathogens (bacteria) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Pathogens (bacteria) | ||
| Disease | Gastric Cancer | Disease Subtypes | / | ||
| Organ | Stomach | Test Sample / Technology Platform | Tumor tissue (16S rRNA sequencing, qPCR), saliva (qPCR) | ||
| Pathobiological Mechanisms | F. nucleatum is enriched in gastric cancer tissues, which promotes inflammation and inhibits T cell function by activating TLR4/NF-κB pathway, and is positively correlated with gastric cancer progression and chemotherapy resistance. Patients with high abundance of F. nucleatum have poor prognosis | ||||
| Clinical Availability Status | Basic research/early clinical: small sample studies have confirmed its prognostic value, which is related to the immunosuppressive microenvironment, and large-scale clinical validation is needed | ||||
| Notes and Dynamics | As a representative of gut/oral microbiota markers, saliva detection is convenient and minimally invasive, and can be used as an auxiliary indicator for the prognosis and immunotherapy response of gastric cancer. F. nucleatum targeted antibiotics (such as metronidazole) combined with immunotherapy may enhance the efficacy | ||||